المؤلفون: Yang JC; Department of Oncology, National Taiwan University Hospital and National Taiwan University Cancer Center, Taipei, Taiwan, Republic of China. Electronic address: chihyang@ntu.edu.tw., Han B; Department of Pulmonary, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, People's Republic of China., De La Mora Jiménez E; Instituto Jalisciense de Cancerologia, Guadalajara, Mexico., Lee JS; Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea., Koralewski P; Ludwik Rydygier Memorial Specialist Hospital, Krakow, Poland., Karadurmus N; Gulhane Training and Research Hospital, Ankara, Turkey., Sugawara S; Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Miyagi, Japan., Livi L; Department of Experimental and Biomedical Sciences Mario Serio, University of Florence and Radiation Oncology Unit, Oncology Department, Azienda Ospedaliero Universitaria Careggi, Florence, Italy., Basappa NS; Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada., Quantin X; IRCM, INSERM, University of Montpellier, ICM, Montpellier, France., Dudnik J; Soroka Medical Center, Beer-Sheva, Israel., Ortiz DM; Fundacion Centro de Investigacion Clinica CIC, Medellin, Colombia., Mekhail T; Advent Health Cancer Institute, Orlando, Florida., Okpara CE; Eisai Ltd., Hatfield, United Kingdom., Dutcus C; Eisai Inc., Nutley, New Jersey., Zimmer Z; Merck & Co., Inc., Rahway, New Jersey., Samkari A; Merck & Co., Inc., Rahway, New Jersey., Bhagwati N; Merck & Co., Inc., Rahway, New Jersey., Csőszi T; Hetenyi Geza Korhaz, Szolnok, Hungary.

المصدر: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2024 Jun; Vol. 19 (6), pp. 941-953. Date of Electronic Publication: 2023 Dec 29.

نوع المنشور: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study

بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 101274235 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1556-1380 (Electronic) Linking ISSN: 15560864 NLM ISO Abbreviation: J Thorac Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Quinolines*/therapeutic use , Carcinoma, Non-Small-Cell Lung*/drug therapy , Carcinoma, Non-Small-Cell Lung*/pathology , Antibodies, Monoclonal, Humanized*/therapeutic use , Lung Neoplasms*/drug therapy , Lung Neoplasms*/pathology , Phenylurea Compounds*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use, Humans ; Male ; Female ; Double-Blind Method ; Middle Aged ; Aged ; Adult ; B7-H1 Antigen/metabolism ; B7-H1 Antigen/antagonists & inhibitors ; Aged, 80 and over

المؤلفون: Lee CH; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Yogesh Shah A; Department of Genitourinary Medical Oncology, MD Anderson Cancer Center, University of Texas, Houston, TX, USA., Rao A; Division of Hematology and Oncology, East Park Medical Group, Houston, TX, USA., Taylor MH; Division of Hematology and Oncology, Earle A. Chiles Research Institute, Providence Portland Medical Center, Portland, OR, USA., Di Simone C; Medical Oncology/Hematology, Arizona Oncology Associates, Tucson, AZ, USA., Hsieh JJ; Department of Medicine, Oncology Division, Washington University School of Medicine, St. Louis, MO, USA., Pinto A; Servicio de Oncología, Hospital Universitario La Paz, Madrid, Spain., Gironés Sarrió R; Medical Oncology Service, Hospital Universitari i Politècnic La Fe, Valencia, Spain., Lee Cohn A; Medical Oncology, US Oncology Research, Rocky Mountain Cancer Center, Denver, CO, USA., Asim Bilen M; Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, USA., Gunnestad Ribe S; Medical Oncology, Sorlandet Hospital Kristiansand, Kristiansand, Norway., Krohn Tennøe Ø; Sykehuset Østfold, Sarpsborg, Norway., Richards D; Department of Oncology, US Oncology Research, Texas Oncology-Tyler, Tyler, TX, USA., Sweis RF; Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL, USA., Courtright J; Department of Oncology, US Oncology Research, Texas Oncology, Dallas, TX, USA., Heinrich D; Department of Oncology and Radiotherapy, Innlandet Hospital Trust, Gjøvik, Norway., Perini R; Clinical Research, Merck & Co. Inc, Rahway, NJ, USA., Kubiak P; Clinical Research, Eisai Inc, Nutley, NJ, USA., Bock D; Biostatistics, Eisai Inc, Nutley, NJ, USA., Okpara CE; Clinical Research, Eisai Ltd, Hatfield, UK., Motzer RJ; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: motzerr@mskcc.org.

المصدر: European urology [Eur Urol] 2024 May 21. Date of Electronic Publication: 2024 May 21.

نوع المنشور: Letter

بيانات الدورية: Publisher: Elsevier Science Country of Publication: Switzerland NLM ID: 7512719 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-7560 (Electronic) Linking ISSN: 03022838 NLM ISO Abbreviation: Eur Urol Subsets: MEDLINE

المؤلفون: González-Martín A; Department of Medical Oncology, Cancer Center Clinica Universidad de Navarra, Madrid, Spain. Electronic address: agonzalezma@unav.es., Chung HC; Department of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea. Electronic address: UNCHUNG8@yuhs.ac., Saada-Bouzid E; Department of Medical Oncology, Centre Antoine Lacassagne, Université Côte d'Azur, Nice, France. Electronic address: Esma.SAADA-BOUZID@nice.unicancer.fr., Yanez E; Oncology-Hematology Unit, University of Frontera, Araucanía, Chile. Electronic address: eduardoyanez.icos@gmail.com., Senellart H; Centre Rene Gauducheau ICO, Saint-Herblain, France. Electronic address: Helene.Senellart@ico.unicancer.fr., Cassier PA; Centre Léon Bérard, Lyon, France. Electronic address: philippe.cassier@lyon.unicancer.fr., Basu B; Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge, UK. Electronic address: bb313@cam.ac.uk., Corr BR; University of Colorado Cancer Center, Aurora, CO, USA. Electronic address: bradley.corr@cuanschutz.edu., Girda E; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA. Electronic address: eg535@cinj.rutgers.edu., Dutcus C; Eisai Inc., Nutley, NJ, USA. Electronic address: Corina_Dutcus@Eisai.com., Okpara CE; Eisai Ltd., Hatfield, United Kingdom. Electronic address: Chinyere_Okpara@eisai.net., Ghori R; Merck & Co., Inc., Rahway, NJ, USA. Electronic address: razi.ghori@merck.com., Jin F; Merck & Co., Inc., Rahway, NJ, USA. Electronic address: fan.jin@merck.com., Groisberg R; Merck & Co., Inc., Rahway, NJ, USA. Electronic address: roman.groisberg@merck.com., Lwin Z; Royal Brisbane and Women's Hospital and University of Queensland, Herston, Queensland, Australia. Electronic address: Zarnie.Lwin@health.qld.gov.au.

المصدر: Gynecologic oncology [Gynecol Oncol] 2024 May 07; Vol. 186, pp. 182-190. Date of Electronic Publication: 2024 May 07.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Academic Press Country of Publication: United States NLM ID: 0365304 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1095-6859 (Electronic) Linking ISSN: 00908258 NLM ISO Abbreviation: Gynecol Oncol Subsets: MEDLINE

المؤلفون: Motzer RJ; Memorial Sloan Kettering Cancer Center, New York, NY., Porta C; University of Bari 'A. Moro,' Bari, Italy.; University of Pavia, Pavia, Italy., Eto M; Kyushu University, Fukuoka, Japan., Powles T; The Royal Free NHS Trust, London, United Kingdom., Grünwald V; University Hospital Essen, Essen, Germany., Hutson TE; Texas Oncology, Dallas, TX., Alekseev B; P.A. Herzen Moscow Oncological Research Institute, Moscow, Russia., Rha SY; Yonsei Cancer Center, Yonsei University Health System, Seoul, South Korea., Merchan J; University of Miami Sylvester Comprehensive Cancer Center, Miami, FL., Goh JC; ICON Research, South Brisbane & Queensland University of Technology, Brisbane, Queensland, Australia., Lalani AA; Juravinski Cancer Centre, McMaster University, Hamilton, Ontario, Canada., De Giorgi U; IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, Meldola, Italy., Melichar B; Palacky University, and University Hospital Olomouc, Olomouc, Czech Republic., Hong SH; Seoul St Mary's Hospital, The Catholic University of Korea, Seoul, South Korea., Gurney H; Macquarie University, Sydney, NSW, Australia., Méndez-Vidal MJ; Maimonides Institute for Biomedical research of Cordoba (IMIBIC) Hospital Universitario Reina Sofía, Medical Oncology Department, Córdoba, Spain., Kopyltsov E; State Institution of Healthcare 'Regional Clinical Oncology Dispensary,' Omsk, Russia., Tjulandin S; N N Blokhin National Medical Research Center for Oncology, Ministry of Health of the Russian Federation, Moscow, Russia., Gordoa TA; Hospital Universitario Ramón y Cajal, Madrid, Spain., Kozlov V; State budgetary Health Care Institution 'Novosibirsk Regional Clinical Oncology Dispensary,' Novosibirsk, Russia., Alyasova A; Prevoljskiy Region Medical Centre, Novgorod, Russia., Winquist E; Western University, London, Ontario, Canada., Maroto P; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain., Kim M; Seoul National University Hospital, Seoul, South Korea., Peer A; Rambam Health Care Campus, Haifa, Israel., Procopio G; Fondazione IRCCS Istituto Nazionale Tumori Milano, Milan, Italy., Takagi T; Tokyo Women's Medical University, Tokyo, Japan., Wong S; Western Health, Melbourne, Victoria, Australia., Bedke J; Department of Urology and Transplantation Surgery, Klinikum Stuttgart, Stuttgart, Germany., Schmidinger M; Department of Urology, Medical University of Vienna, Vienna, Austria., Rodriguez-Lopez K; Merck & Co, Inc, Rahway, NJ., Burgents J; Merck & Co, Inc, Kenilworth, NJ., He C; Eisai Inc, Nutley, NJ., Okpara CE; Eisai Ltd, Hatfield, UK., McKenzie J; Eisai Inc, Nutley, NJ., Choueiri TK; Dana-Farber Cancer Institute, Boston, MA.

مؤلفون مشاركون: CLEAR Trial Investigators

المصدر: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 Apr 10; Vol. 42 (11), pp. 1222-1228. Date of Electronic Publication: 2024 Jan 16.

نوع المنشور: Randomized Controlled Trial; Clinical Trial, Phase III; Journal Article

بيانات الدورية: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Carcinoma, Renal Cell*/pathology , Kidney Neoplasms*/pathology , Phenylurea Compounds* , Quinolines* , Antibodies, Monoclonal, Humanized*, Humans ; Sunitinib/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Survival Analysis

المؤلفون: Grünwald V; Clinic for Medical Oncology and Clinic for Urology, University Hospital Essen, Essen, Germany., Powles T; Barts Cancer Institute and the Royal Free Hospital, Queen Mary University of London, London, United Kingdom., Eto M; Department of Urology, Kyushu University, Fukuoka, Japan., Kopyltsov E; State Institution of Healthcare Regional Clinical Oncology Dispensary, Omsk, Russia., Rha SY; Department of Internal Medicine, Yonsei Cancer Center, Yonsei University Health System, Seoul, Republic of Korea., Porta C; Department of Biomedical Sciences and Human Oncology, University of Bari 'A. Moro', Bari, Italy., Motzer R; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States., Hutson TE; Medical Oncology, Texas Oncology, Dallas, TX, United States., Méndez-Vidal MJ; Department of Oncology, Maimonides Institute for Biomedical Research of Córdoba (IMIBIC) Hospital Universitario Reina Sofía, Córdoba, Spain., Hong SH; Department of Urology, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea., Winquist E; Department of Oncology, University of Western Ontario, London, ON, Canada., Goh JC; ICON Research, South Brisbane & University of Queensland, St Lucia, QLD, Australia., Maroto P; Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain., Buchler T; Department of Oncology, Charles University and Thomayer University Hospital, Prague, Czechia., Takagi T; Department of Urology, Tokyo Women's Medical University, Tokyo, Japan., Burgents JE; Global Clinical Development, Merck & Co., Inc., Rahway, NJ, United States., Perini R; Clinical Research, Merck & Co., Inc., Rahway, NJ, United States., He C; Biostatistics, Eisai Inc., Nutley, NJ, United States., Okpara CE; Clinical Research, Eisai Ltd., Hatfield, United Kingdom., McKenzie J; Clinical Research, Eisai Inc., Nutley, NJ, United States., Choueiri TK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.

المصدر: Frontiers in oncology [Front Oncol] 2024 Mar 01; Vol. 13, pp. 1343027. Date of Electronic Publication: 2024 Mar 01 (Print Publication: 2023).

نوع المنشور: Published Erratum

بيانات الدورية: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE

المؤلفون: Matsubara N; National Cancer Center Hospital East, Chiba, Japan., de Wit R; Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Balar AV; Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA., Siefker-Radtke AO; The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Zolnierek J; LUX MED Onkologia Hospital, Warsaw, Poland., Csoszi T; Jász-Nagykun-Szolnok County Hospital, Szolnok, Hungary., Shin SJ; Yosnei University College of Medicine, Seoul, South Korea., Park SH; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea., Atduev V; Volga District Medical Center, Federal Medical-Biological Agency, Nizhny Novgorod, Russia., Gumus M; Istanbul Medeniyet University, Istanbul, Turkey., Su YL; Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan., Karaca SB; Tülay Aktaş Onkoloji Hastanesi, İzmir Bornova, Turkey., Cutuli HJ; Institute for Diagnosis and Metabolic Research (IDIM), Buenos Aires, Argentina., Sendur MAN; Ankara Yildirim Beyazıt University Faculty of Medicine and Ankara City Hospital, Ankara, Turkey., Shen L; Merck & Co., Inc., Rahway, NJ, USA., O'Hara K; Eisai LTD, Hatfield, UK., Okpara CE; Eisai LTD, Hatfield, UK., Franco S; Merck & Co., Inc., Rahway, NJ, USA., Moreno BH; Merck & Co., Inc., Rahway, NJ, USA., Grivas P; University of Washington, Fred Hutchinson Cancer Center, Seattle, WA, USA. Electronic address: pgrivas@uw.edu., Loriot Y; Gustave Roussy, Cancer Campus, Villejuif, France; Université Paris-Saclay, Villejuif, France. Electronic address: Yohann.loriot@gustaveroussy.fr.

المصدر: European urology [Eur Urol] 2024 Mar; Vol. 85 (3), pp. 229-238. Date of Electronic Publication: 2023 Sep 29.

نوع المنشور: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial

بيانات الدورية: Publisher: Elsevier Science Country of Publication: Switzerland NLM ID: 7512719 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-7560 (Electronic) Linking ISSN: 03022838 NLM ISO Abbreviation: Eur Urol Subsets: MEDLINE

مواضيع طبية MeSH: Carcinoma, Transitional Cell*/pathology , Phenylurea Compounds* , Quinolines* , Urinary Bladder Neoplasms*/drug therapy , Urinary Bladder Neoplasms*/pathology, Humans ; Antibodies, Monoclonal, Humanized/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects

المؤلفون: Colombo N; Gynecologic Oncology Department, European Institute of Oncology IRCCS, Milan, Italy.; Department of Medicine and Surgery, University of Milan-Bicocca, Italy., Lorusso D; Division of Gynecologic Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS and Catholic University of Sacred Heart, Rome, Italy., Monk BJ; HonorHealth Research Institute, University of Arizona, Creighton University, Phoenix, AZ, USA., Slomovitz B; Division of Gynecologic Oncology, Mount Sinai Medical Center, Miami Beach, FL, USA., Hasegawa K; Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan., Nogueira-Rodrigues A; Universidade Federal de Minas Gerais (UFMG), Brazilian Group of Gynecologic Oncology (EVA), Grupo Oncoclínicas, DOM Oncologia, Brazil., Zale M; Clinical Safety & Risk Management Late-Stage Oncology - Gynecologic Cancers, Merck & Co., Inc., Rahway, NJ, USA., Okpara CE; Clinical Research, Eisai Ltd., Hatfield, UK., Barresi G; Merck & Co., Inc., Switzerland., McKenzie J; Oncology Business Group, Eisai Inc., Nutley, NJ, USA., Makker V; Department of Medicine, Memorial Sloan Kettering Cancer Center; Weill Cornell Medical Center, New York, NY, USA.

المصدر: The oncologist [Oncologist] 2024 Jan 05; Vol. 29 (1), pp. 25-35.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Oxford University Press Country of Publication: England NLM ID: 9607837 Publication Model: Print Cited Medium: Internet ISSN: 1549-490X (Electronic) Linking ISSN: 10837159 NLM ISO Abbreviation: Oncologist Subsets: MEDLINE

مواضيع طبية MeSH: Endometrial Neoplasms*/drug therapy , Hypertension*/drug therapy , Hypothyroidism* , Musculoskeletal Diseases*/drug therapy , Musculoskeletal Diseases*/etiology, Female ; Humans ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Diarrhea/drug therapy ; Fatigue/etiology

المؤلفون: Grünwald V; Clinic for Medical Oncology and Clinic for Urology, University Hospital Essen, Essen, Germany., Powles T; Barts Cancer Institute and the Royal Free Hospital, Queen Mary University of London, London, United Kingdom., Eto M; Department of Urology, Kyushu University, Fukuoka, Japan., Kopyltsov E; State Institution of Healthcare Regional Clinical Oncology Dispensary, Omsk, Russia., Rha SY; Department of Internal Medicine, Yonsei Cancer Center, Yonsei University Health System, Seoul, Republic of Korea., Porta C; Department of Biomedical Sciences and Human Oncology, University of Bari 'A. Moro', Bari, Italy., Motzer R; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States., Hutson TE; Medical Oncology, Texas Oncology, Dallas, TX, United States., Méndez-Vidal MJ; Department of Oncology, Maimonides Institute for Biomedical Research of Córdoba (IMIBIC) Hospital Universitario Reina Sofía, Córdoba, Spain., Hong SH; Department of Urology, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea., Winquist E; Department of Oncology, University of Western Ontario, London, ON, Canada., Goh JC; ICON Research, South Brisbane & University of Queensland, St Lucia, QLD, Australia., Maroto P; Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain., Buchler T; Department of Oncology, Charles University and Thomayer University Hospital, Prague, Czechia., Takagi T; Department of Urology, Tokyo Women's Medical University, Tokyo, Japan., Burgents JE; Global Clinical Development, Merck & Co., Inc., Rahway, NJ, United States., Perini R; Clinical Research, Merck & Co., Inc., Rahway, NJ, United States., He C; Biostatistics, Eisai Inc., Nutley, NJ, United States., Okpara CE; Clinical Research, Eisai Ltd., Hatfield, United Kingdom., McKenzie J; Clinical Research, Eisai Inc., Nutley, NJ, United States., Choueiri TK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.

المصدر: Frontiers in oncology [Front Oncol] 2023 Aug 16; Vol. 13, pp. 1223282. Date of Electronic Publication: 2023 Aug 16 (Print Publication: 2023).

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE

المؤلفون: Pearson AD; ACCELERATE, Europe. Electronic address: andy1pearson@btinternet.com., Gaspar N; Gustave Roussy Cancer Centre, Paris, France., Janeway K; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, USA., Campbell-Hewson Q; Great North Children's Hospital, Newcastle, UK., Lawlor ER; Ben Towne Center for Childhood Cancer Research, Seattle Children's Research Institute, Seattle, WA, USA; Department of Pediatrics, University of Washington, Seattle, WA, USA., Copland C; ACCELERATE, Europe; Euro Ewings Consortium, Europe, UK., Karres D; Paediatric Medicines Office, Scientific Evidence Generation Department, Human Division, European Medicines Agency (EMA), Netherlands., Norga K; Antwerp University Hospital, Antwerp, Belgium; Paediatric Committee of the European Medicines Agency (EMA), Netherlands; Federal Agency for Medicines and Health Products, Belgium., Benzaghou F; Ipsen Pharma, Cambridge, MA, USA., Weiner S; Children's Cancer Cause, USA., Weigel B; University of Minnesota, Minneapolis, USA., Weiss AR; Maine Medical Center, Portland, ME, USA., Strauss SJ; University College London, London, UK., Smith M; National Cancer Institute, USA., Setty BA; Division of Pediatric Hematology/Oncology/Bone Marrow Transplantation, Nationwide Children's Hospital, Columbus, OH, USA., Seibel N; National Cancer Institute, USA., Scobie N; Zoe4Life, Switzerland., Pappo A; St Jude Children's Research Hospital, USA., Okpara CE; Eisai GmbH, Frankfurt, Germany., Nysom K; Righospitalet, Denmark., McDonough J; The Andrew McDonough B+ Foundation, USA., Marshall LV; The Royal Marsden Hospital, London, UK; The Institute of Cancer Research, London, UK., Ludwinski D; Solving Kids' Cancer, USA., Ligas F; Paediatric Medicines Office, Scientific Evidence Generation Department, Human Division, European Medicines Agency (EMA), Netherlands., Lesa G; Paediatric Medicines Office, Scientific Evidence Generation Department, Human Division, European Medicines Agency (EMA), Netherlands., Knudsen S; Allarity Therapeutics, MA, USA., Kauh J; HUTCHMED International Corporation, USA., Hsieh A; Blueprint Medicines, Boston, MA, USA., Heenen D; KickCancer, Belgium., Hawkins DS; Seattle Children's Hospital, USA; Children's Oncology Group, USA., Graham A; MIB Agents, Osteosarcoma Alliance, USA., Garmey E; Oncoheroes Biosciences, Boston, MA, USA., DuBois SG; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, USA., Fox E; St Jude Children's Research Hospital, USA., Donoghue M; US Food and Drug Administration, USA., de Rojas T; ACCELERATE, Europe., Chung J; Bayer Healthcare Pharmaceuticals, Whippany, NJ, USA., Casanova M; Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy., Brennan B; Royal Manchester Children's Hospital, Manchester, UK., Bishop M; St Jude Children's Research Hospital, USA., Buenger V; Coalition Against Childhood Cancer (CAC2), USA., Reaman G; US Food and Drug Administration, USA., Vassal G; ACCELERATE, Europe; Gustave Roussy Cancer Centre, Paris, France.

المصدر: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2022 Sep; Vol. 173, pp. 71-90. Date of Electronic Publication: 2022 Jul 18.

نوع المنشور: Journal Article; Review; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9005373 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0852 (Electronic) Linking ISSN: 09598049 NLM ISO Abbreviation: Eur J Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Bone Neoplasms*/drug therapy , Osteosarcoma*/drug therapy, Adolescent ; Adult ; Child ; Humans ; Neoplasm Recurrence, Local ; Prospective Studies ; Retrospective Studies ; United States ; United States Food and Drug Administration

المؤلفون: Motzer RJ; Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center, New York, NY, USA., Taylor MH; Division of Hematology and Oncology, Earle A. Chiles Research Institute, Providence Portland Medical Center, Portland, OR, USA., Evans TRJ; Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.; Medical Oncology, Beatson West of Scotland Cancer Centre, Glasgow, UK., Okusaka T; Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan., Glen H; Medical Oncology, Beatson West of Scotland Cancer Centre, Glasgow, UK., Lubiniecki GM; Global Clinical Development, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA., Dutcus C; Clinical Research, Eisai Inc., Nutley, NJ, USA., Smith AD; Clinical Research, Eisai Inc., Nutley, NJ, USA., Okpara CE; Clinical Research, Eisai Inc., Nutley, NJ, USA., Hussein Z; Clinical Pharmacology Science, Eisai Europe Ltd, Hatfield, UK., Hayato S; Clinical Pharmacology Science, Eisai Co., Ltd, Tokyo, Japan., Tamai T; Clinical Research, Eisai Co., Ltd, Tokyo, Japan., Makker V; Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center, New York, NY, USA.

المصدر: Expert review of anticancer therapy [Expert Rev Anticancer Ther] 2022 Apr; Vol. 22 (4), pp. 383-400. Date of Electronic Publication: 2022 Apr 07.

نوع المنشور: Journal Article; Review; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Taylor & Francis Country of Publication: England NLM ID: 101123358 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8328 (Electronic) Linking ISSN: 14737140 NLM ISO Abbreviation: Expert Rev Anticancer Ther Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents*/adverse effects , Carcinoma, Renal Cell*/pathology , Kidney Neoplasms*/drug therapy , Liver Neoplasms*/drug therapy , Quinolines*/adverse effects , Thyroid Neoplasms*/drug therapy , Thyroid Neoplasms*/pathology, Humans ; Iodine Radioisotopes ; Phenylurea Compounds/adverse effects ; Protein Kinase Inhibitors/adverse effects